Literature DB >> 30496881

Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?

John T Lucas1, M Beth McCarville2, David A Cooper3, Mikhail Doubrovin2, Daniel Wakefield3, Teresa Santiago4, Yimei Li5, Xingyu Li5, Matthew Krasin6, Victor Santana7, Wayne Furman8, Andrew M Davidoff9.   

Abstract

PURPOSE: The predictive value of Image-Defined Risk Factors (IDRFs) developed by the International Neuroblastoma Risk Group Task Force as it relates to primary-site management is undefined and may aid patient selection for de-escalation of adjuvant radiation therapy to the primary site in high-risk neuroblastoma. METHODS AND MATERIALS: Patients (N = 76) with high-risk neuroblastoma treated on prospective trials at our institution from 1997 to 2014 were eligible for inclusion. IDRFs were defined based on pretherapy imaging. Overall survival, progression-free survival, and locoregional failure-free survival (LRFFS) were described using the Kaplan-Meier estimator and tested across strata by using the log-rank test.
RESULTS: Twenty of 76 patients (26%) experienced local (n = 6), regional (n = 6), or combined locoregional failure (n = 8) with or without distant failure. Ten (50%) of the locoregional failures had concurrent distant relapse. Of patients who completed all therapy, both those with no IDRFs and those with >90% resection had a 3-year LRFFS of 100%, with or without radiation therapy. Patients with either ≥1 IDRF or <Gross Total Resection (GTR) or the inability to complete all therapy had inferior 3-year LRFFS of 77.8% and 14.4% with or without radiation therapy, respectively (P < .04). Patients treated with a dose ≥30.6 Gy as part of therapy for residual disease had an 83.3% locoregional control rate.
CONCLUSIONS: Patients with >90% tumor resection and no primary site IDRFs at diagnosis may be candidates for de-escalation of adjuvant primary-site radiation therapy, although validation of these findings in future studies is required.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30496881      PMCID: PMC8810202          DOI: 10.1016/j.ijrobp.2018.11.041

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  44 in total

1.  Value of surgical resection in children with high-risk neuroblastoma.

Authors:  Brian R Englum; Kristy L Rialon; Paul J Speicher; Brian Gulack; Timothy A Driscoll; Susan G Kreissman; Henry E Rice
Journal:  Pediatr Blood Cancer       Date:  2015-03-23       Impact factor: 3.167

2.  Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes.

Authors:  Stefano Avanzini; Luca Pio; Giovanni Erminio; Claudio Granata; Keith Holmes; Marion Gambart; Piero Buffa; Victoria Castel; Dominique Valteau Couanet; Alberto Garaventa; Angela Pistorio; Giovanni Cecchetto; Giuseppe Martucciello; Girolamo Mattioli; Sabine Sarnacki
Journal:  Pediatr Blood Cancer       Date:  2017-04-25       Impact factor: 3.167

3.  Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.

Authors:  Daniel von Allmen; Andrew M Davidoff; Wendy B London; Collin Van Ryn; Daphne A Haas-Kogan; Susan G Kreissman; Geetika Khanna; Nancy Rosen; Julie R Park; Michael P La Quaglia
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

4.  Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

Authors:  Thomas H Beckham; Dana L Casey; Michael P LaQuaglia; Brian H Kushner; Shakeel Modak; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-11       Impact factor: 7.038

5.  Is complete resection of high-risk stage IV neuroblastoma associated with better survival?

Authors:  Fanny Yeung; Patrick Ho Yu Chung; Paul Kwong Hang Tam; Kenneth Kak Yuen Wong
Journal:  J Pediatr Surg       Date:  2015-08-28       Impact factor: 2.545

6.  Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.

Authors:  Shravan Kandula; Roshan S Prabhu; Ronica Nanda; Jeffrey M Switchenko; Thomas Cash; Muna Qayed; Howard Katzenstein; Natia Esiashvili
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

7.  Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.

Authors:  D Strother; J van Hoff; P V Rao; E I Smith; R C Shamberger; E C Halperin; K J Murray; R P Castleberry
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

8.  Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.

Authors:  B H Kushner; S Wolden; M P LaQuaglia; K Kramer; D Verbel; G Heller; N K Cheung
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

9.  Differential attenuation of clavicle growth after asymmetric mantle radiotherapy.

Authors:  Thomas E Merchant; Lan Nguyen; Duyen Nguyen; Shengje Wu; Melissa M Hudson; Sue C Kaste
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

10.  Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.

Authors:  Daphne A Haas-Kogan; Patrick S Swift; Michael Selch; Gerald M Haase; Robert C Seeger; Robert B Gerbing; Daniel O Stram; Katherine K Matthay
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

View more
  3 in total

Review 1.  Neuroblastoma.

Authors:  Christine Chung; Tom Boterberg; John Lucas; Joseph Panoff; Dominique Valteau-Couanet; Barbara Hero; Rochelle Bagatell; Christine E Hill-Kayser
Journal:  Pediatr Blood Cancer       Date:  2021-05       Impact factor: 3.167

2.  Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.

Authors:  William C Temple; Kieuhoa T Vo; Katherine K Matthay; Brunilda Balliu; Christina Coleman; Jennifer Michlitsch; Andrew Phelps; Spencer Behr; Matthew A Zapala
Journal:  Cancer Med       Date:  2020-12-13       Impact factor: 4.452

3.  Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma.

Authors:  Jian-Guo Zhou; Bo Liang; Su-Han Jin; Hui-Ling Liao; Guo-Bo Du; Long Cheng; Hu Ma; Udo S Gaipl
Journal:  Front Oncol       Date:  2019-12-04       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.